Bionomics Limited Completes Enrollment for BNC105 Phase II Renal Cancer Trial
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ADELAIDE, South Australia, June 10, 2013 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) has completed enrolment into a randomized Phase II clinical trial testing the combination of BNC105 plus everolimus (Afinitor) to treat patients with advanced renal cell carcinoma, the DisrupTOR-1 clinical trial.
Help employers find you! Check out all the jobs and post your resume.
ADELAIDE, South Australia, June 10, 2013 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) has completed enrolment into a randomized Phase II clinical trial testing the combination of BNC105 plus everolimus (Afinitor) to treat patients with advanced renal cell carcinoma, the DisrupTOR-1 clinical trial.
Help employers find you! Check out all the jobs and post your resume.